What we do

Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.


Omixon Blog

Omixon Holotype HLA Validation Alpha Study Featured at ASHI Annual Meeting 2014

Omixon announce today that Holotype HLA™ and other Omixon products will be featured in five posters and three oral presentations at the annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) held from October 20-24 in Denver, CO. …more

By kriszta.katona 0 comments

SeqGene is Omixon’s New Distributor

Omixon is pleased to announce the signature of a Distribution Agreement with SeqGene, based in Taipei City, Taiwan. The agreement is effective 1st October, 2014. About SeqGene: SeqGene is a molecular biology company. They specialize in next generation sequencing (NGS)-based …more

By kriszta.katona 0 comments